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1. Introduction
Generalized anxiety disorder (GAD) is defined in the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV) as the presence of persistent, excessive anxiety
and worry about a number of events and activities occurring on most of the days for at least
6 months. The patient must also experience at least three of the following six symptoms:
restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or
mind going blank, irritability, muscle tension, and sleep disturbance.
GAD has a 12-month prevalence of 1% – 2.1% and a lifetime prevalence of 2.8% – 4.1% in
Europe and in the US (Grant et al., 2005), often occurs early in life with twice the number of
women suffering from it compared to men (ESEMeD/MHEDEA Investigators, 2000). GAD is
chronic and disabling, and is associated with high rates of psychiatric comorbidity and sub‐
stantial personal, social and economic costs (Wittchen et al., 1994; Ballenger et al., 2001;
Wittchen, 2002). Evidence shows GAD’s impact on social functioning, distress levels, and
utilization of medical care is equivalent to those of other major psychiatric disorders (Men‐
nin et al. 2004). In the National Comorbidity Survey, Wittchen and colleagues found that
~38% of patients with GAD may have another anxiety disorder and 48% may have major
depression in addition to GAD (Wittchen et al., 1994). In addition to psychiatric comorbidi‐
ties, patients with anxiety disorders have a higher risk for developing medical diseases in
the areas of cardiovascular, gastrointestinal and respiratory as compared with control
groups (Bowen et al., 2000).
Remission criteria defined by Ballenger include no or minimal symptoms of anxiety (Hamil‐
ton Anxiety Scale score ≤7-10), no functional impairment (Sheehan Disability Scale score ≤1
on each item) and no or minimal symptoms of depression (Hamilton Depression Scale score
≤7) for generalized anxiety disorder (Ballenger, 1999). Remission rates are considerably low
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in generalised anxiety disorder. Yonkers and colleagues have shown that the remission rates
are only 15% and 25% among 164 patients after one and two years respectively (Yonkers et
al., 1996). The probability of remission of GAD is only 38% at 5 years, and the probability of
relapse after remission is 27-39% by 3 years (Yonkers et al., 2000).
GAD is often unrecognized or misdiagnosed as a physical condition due to the range of clin‐
ical presentations, including somatic symptoms, and the frequent occurrence of comorbid
conditions. The main treatment approaches for GAD comprise pharmacotherapy or psycho‐
therapy or a combination of both. The chronic and disabling nature of GAD often means
that some individuals may fail to respond fully to first-line treatment (Bandelow et al., 2008;
Goodwin et al., 2002; Altamura et al., 2008; Allgulander et al., 2002; Baldwin et al; 2005). Pa‐
tients may therefore require a sequential trial of treatments or possibly a combination thera‐
py (Davidson et al; 2010).
Research in the treatment of GAD has primarily focused on the efficacy of pharmacothera‐
py. Antidepressant and anxiolytic drugs are the two most commonly used pharmacological
treatments for anxiety disorders. Newer anticonvulsant and sometimes antipsychotic drugs
are also used in the treatment of some anxiety disorders including generalized anxiety dis‐
order. More recently, there has been an increasing interest in the efficacy of psychotherapy.
Of all the therapies, cognitive behavioral therapy (CBT) has established the most empirical
support as an effective treatment for GAD (Gould et al. 2004).
In recent years, GAD-related disability (Wittchen, 2002) as well as impairment in quality of
life and functioning has gain importance. Anxiety disorders result in considerable economic
loss both decreasing working performance and increasing the number of applications for
health care services (Wittchen, 2002; DuPont et al., 1996; Greenberg et al., 1999 ). GAD poses
both personal and public substantial economic and social burden (Pollack et al., 2009).
According to the preliminary findings of our ongoing study on the evaluation of patient
burden due to wrong diagnosis and treatment in patients with generalized anxiety disorder
(GAD), the mean duration of GAD was 5.6±6.1 years, and the patients received initial treat‐
ment for their GAD 27.6±36.7 for months ago. It was noted that GAD was mostly accompa‐
nied by major depression (60.5%), followed by other anxiety disorders (31.6%). Of the
patients diagnosed with GAD, 86.4% were using medication for GAD and 40.9% were ad‐
mitted to an emergency service for any reason within the last 6 months. The mean number
of emergency admissions was 3.1±3.7. Of the patients admitted to emergency services, 51.9%
underwent analyses such as blood analysis, radiological examination, electrocardiography
(ECG) and ultrasonography (USG), and 48.5% were referred to another specialist for consul‐
tation. The preliminary findings of the present study indicate that admissions of GAD pa‐
tients to emergency services due to various complaints continue when these patients are not
treated adequately and sufficiently, and that financial burden of this disorder increases in‐
crementally due to laboratory analyses and imaging techniques, consultations and addition‐
al therapies performed during these admissions (Dilbaz and Karamustafalıoğlu 2012a).
This chapter presents the unmet needs in the treatment of generalised anxiety disorders and
new strategies in treatment for GAD.
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2. Treatment
The primary goal of treatment of GAD is to alleviate psychic and somatic complaints, pro‐
mote sleep, improve patient’s functioning and enhance patient quality of life. Besides, treat‐
ing other concomitant medical conditions (psychiatric and/or medical co-morbidity) and
consequently providing remission and preventing relapses are also aimed. The important
requirements for the therapy drug include rapid action, broad spectrum, increasing remis‐
sion rates, preventing relapses, absence of symptoms due to discontinuation of drug, mini‐
mum interaction with other drugs, and safety for elderly and children (Dilbaz et al., 2011;
Davidson et al., 2010). Treatment of GAD comprises drug therapy together with behavioral
therapy and psychotherapy. Characteristics and severity of symptoms, co-morbidities, pres‐
ence of substance addiction and risk for suicide, results of previous therapies, costs, availa‐
bility of drug and patient preference should be considered while planning GAD treatment
(Davidson et al., 2010).
2.1. Pharmacological strategies
2.1.1. Benzodiazepines
Many randomized, double-blind trials have demonstrated the efficacy of benzodiazepines in
the acute treatment of GAD (Greenblatt et al., 1983; Rickels et al., 1987; Hollister et al., 1993).
However, there is evidence that more than a third of patients will not meet remission criteria
in the treatments with benzodiazepines (Shader and Greenblatt, 1983).
The risks and benefits of using benzodiazepines should be carefully considered in each pa‐
tient. Benzodiazepines have rapid onset, relatively low toxicity, and anxiolytic potency but
these benefits should be weighed against for potential motor impairment, dependence and
withdrawal symptoms esspecially when prescribed for >4 weeks (Rynn and Brawman-Min‐
tzer, 2004).
Particularly in older people, benzodiazepine use can be problematic due to side effects such
as falls, memory impairment, incoordination, drowsiness, and confusion (Petrovic et al.,
2003). They can also disrupt sleep architecture, and rebound insomnia may occur after stop‐
ping treatment (Longo and Johnson, 2000).
2.1.2. Antidepressants
Selective serotonin reuptake inhibitors (SSRIs), serotonin noradrenalin reuptake inhibitors
(SNRIs), tricyclic antidepressants (TCAs, particularly imipramine), and, in a single control‐
led trial, trazodone have demonstrated efficacy in treatment of GAD compared to placebo
(Rickels et al., 1993). Several analyses have shown similar efficacy among antidepressant
agents in the management of GAD (Kapczinski et al, 2003).
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2.1.2.1. SSRIs and SNRIs
Of these, SSRIs and SNRIs are the recommended first-line drugs for treatment of anxiety
based on strength of evidence and acceptable tolerability. Antidepressants, particularly
SSRI, may be associated with an initial worsening of anxiety symptoms in some patients. A
retrospective cohort study defined characteristics of patients which developed emergent
anxiety following an antidepressant intiation as young age, white and women sex (Li et al.,
2011). Li et al. also found that receiving bupropion, fluoxetine or sertraline had lower risk of
anxiety development than citalopram, paroxetine, venlafaxine and mirtazapine (Li et al,
2009). It is recommended to start on low doses and slowly titrate up to a therapeutic dose to
reduce these “activation” symptoms (Sinclair et al., 2009). Patients should be advised of the
potential for initial increase/worsening of symptoms and the likely delay of clinical effect
(some response often seen by 4 weeks). Patient awareness of these factors when commenc‐
ing SSRI treatment assists in reducing early discontinuation of treatment. Concomitant use
of benzodiazepines during early treatment with SSRI may be useful in moderating these
“activation effects” of SSRI early in treatment, although the potential for dependence must
be considered. SSRI need to be taken for up to 12 weeks in order to assess a patient’s re‐
sponse to treatment. Dosing requirements (like initiation in lower doses and reaching opti‐
mal doses by weekly increments) for antidepressants differ to that needed in the treatment
of depression. All patients being treated with antidepressants (irrespective of diagnosis)
should be monitored for worsening of their clinical condition and the emergence of suicidal
ideation (Anxiety Disorders – Drug Treatment Guidelines, 2008)
According to Western Australian Psychotropic Drugs Committee; sertralin, escitalopram and
venlafaxin have second line of evidence in treatment of generalized anxiety disorders whereas
paroxetine has first line evidence (Hidalgo et al., 2007; Kapczinski et al., 2003; Anxiety Disor‐
ders – Drug Treatment Guidelines, 2008). There was a small statistically significance in favour
of escitalopram compared with paroxetine based on a reduction in HAM-A scores. In addi‐
tion, there was a 40% reduction in risk of non-response and lower risk (although not statistical‐
ly  significant)  of  discontinuation  of  treatment  due  to  adverse  events  for  escitalopram
compared with paroxetine (Baldwin et al., 2006). There were no statistically significant differ‐
ences found between paroxetine and sertraline on any outcomes (Ball et al., 2005).
There were no differences found on reduction of anxiety symptoms between escitalopram
and venlafaxine while venlafaxine was associated with a greater risk of discontinuation (al‐
though this was not statistically significant) (Bose et al., 2008). Duloxetine was found to be
effective in 60-120 mg/d doses in treatment of generalised anxiety disorder when compared
to placebo (Rynn et al., 2008; Hartford et al., 2007). No difference was found between dulox‐
etine and venlafaxine for reduction in anxiety and discontinuation due to adverse events
(Nicolini et al; 2009).
2.1.2.2. Bupropion
Bystritsky and colleagues compared bupropion XL and escitalopram in 24 patients with
generalised anxiety disorder in a 12-week, double-blind, randomized controlled trial and re‐
ported comparable efficacy between bupropion and escitalopram (2008).
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2.1.2.3. Agomelatine
The efficacy of 25 to 50 mg/day agomelatine in generalised anxiety disorder (GAD) was as‐
sessed in a 12-week double-blind, placebo-controlled study of 121 patients with no comor‐
bid disorders (Stein et al., 2008). Agomelatine was found more effective than placebo at
reducing anxiety (based on Hamilton rating scale for Anxiety; p=0.04). Agomelatine also im‐
proved sleep symptoms, sleep latency (p≤0.001), quality of sleep (p=0.002) and awakenings
(p≤0.0001).
2.1.3. Anticonvulsants
2.1.3.1. Valproate
Valproate has been investigated for the management of GAD in a double-blind, placebo-
controlled randomized trial involving 80 male patients with GAD in a double-blind placebo-
controlled design (Aliyev and Aliyev, 2008). 40 patients randomized to receive 500 mg
valproate three times per day and 40 patients received mathed plasebo. At week 4, valproate
separated from placebo by mean total HARS score, and at 6 weeks, the mean change in
HARS score reached significance. The most common side effects in the valproate group
were dizziness and nausea and further investigation is recommended.
2.1.3.2. Gabapentine
Pollack and colleagues reported two cases documenting improvements in patients with
GAD, following addition of gabapentin to their treatment (Pollack et al., 1998).
2.1.3.3. Tiagabine
There are case series documenting patients with generalised anxiety disorder treated with
tiagabine successfully (Schwarts, 2002; Crane et al., 2003; Schaller et al., 2004). Schwartz et al
followed up 17 patients with GAD in an 8-week, open-label trial of tiagabine (mean dose 13
mg/d) augmentation to SSRIs or benzodiazepines. 76% of patients responded [≥ 50% reduc‐
tion in anxiety symptoms (HARS)] and 59% achieved remission (HARS score ≤ 7) (Schwartz
et al., 2005).
Pollack et al reported on 3 large 10-week, randomized, double-blind, placebo-controlled,
parallel-group studies. In the fixed-dose study, 910 patients received 4, 8, or 12 mg/d of tia‐
gabine and in two flexible-dose studies, a total of 920 participants were enrolled. The mean
doses of tiagabine were 8.9 and 9.2 mg/d. Neither study found significant differences in
anxiety symptoms (HARS used) when compared to placebo and investigators concluded
that these studies do not support the efficacy of tiagabine in adult patients with GAD (Pol‐
lack et al., 2008).
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2.1.3.4. Pregabaline
There have been several industry-sponsored, multicenter, outpatient, prospective, random‐
ized, double-blind, placebo-controlled studies. Pande et al. showed a significant improve‐
ment with pregabalin compared to placebo, but no significant differences in response were
observed when comparing pregabalin 50 mg tid to pregabalin 200 mg tid or lorazepam to
pregabalin 200 mg tid. The most commonly associated adverse events with pregabalin were
dizziness, somnolence, and headache (Pande et al., 2003). Feltner and colleagues also com‐
pared pregabalin (in different doses), lorazepam 2 mg tid, or placebo. They also found pre‐
gabalin 200 mg tid effective in treatment of GAD, however, pregabalin 50 mg tid wasn’t
effective and 200 mg tid was not significantly different from lorazepam (Feltner et al., 2003).
Pohl et al. found pregabalin in 100 mg bid, 200 mg bid, and 150 mg tid doses significantly
effective than in reducing anxiety symptoms (Pohl et al., 2005).
In another large study of 454 participants with GAD, Rickels et al. compared pregabaline (in
different doses) with alprazolam and placebo. Investigators reported that of the 5 treatment
groups, the 300-mg pregabalin group was the only medication group that differed statisti‐
cally in global improvement at treatment end point not only from the placebo group but also
from the alprazolam group (Rickels et al., 2005). Another study found pregabaline (400-600
mg/day) effective in treatment of GAD compared to placebo and safer than venlafaxine
(Montgomery et al., 2006).
Lydiard et al combined data from 6 short-term, double-blind, placebo-controlled, fixed-dose
trials of pregabalin for the treatment of GAD. They concluded that pregabalin had signifi‐
cant efficacy in treating both HARS psychic and somatic anxiety measures. Furthermore,
they indicated that a dose-response effect was evident for pregabalin that appeared to reach
a plateau at a dose of 300 mg/d (Lydiard et al., 2010).
Pregabalin is promising in both add-on and switch therapies in treatment-resistant GAD
cases. Pregabalin rapidly (within days) relieves anxiety symptoms providing substantial ad‐
vantage over SSRI and SNRIs (Dilbaz and Karamustafalıoğlu, 2012a).
2.1.3.5. Levetiracetam
One case with GAD reported by Pollack, had improved with levetiracetam 250 mg/d added
to citalopram treatment (Pollack, 2002).
2.1.4. Atypical antipsychotics
Some first-generation antipsychotics were approved for a condition similar to GAD, and re‐
cent studies have suggested that atypical antipsychotics may also have a role in GAD. A Co‐
chrane metaanalysis reported that nine studies investigated the effects of second-generation
antipsychotics in generalised anxiety disorder. Seven of them investigated the effects of que‐
tiapine. Participants with generalised anxiety disorder responded significantly better to que‐
tiapine than to placebo (4 RCTs, N = 2265, OR = 2.21, 95% CI 1.10 to 4.45). However, patients
on quetiapine arm were more likely to drop out due to adverse events, like gain weight or
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sedation. When quetiapine was compared with antidepressants in GAD, there was no signif‐
icant difference in efficacy-related outcomes, but more participants in the quetiapine groups
dropped out due to adverse events.
2.1.4.1. Quetiapine
Several preliminary reports of monotherapy trials of quetiapine versus placebo have descri‐
bed efficacy at doses in the range of 50–150 mg/d (Chouinard et al., 2008; Khan et al., 2008;
Joyce et al., 2008; Bandelow et al., 2009), but quetiapine cannot yet be recommended as a
routine GAD treatment until a full description of efficacy and safety from these studies have
been published. However, the use of quetiapine could be considered after other classes of
drugs have proved ineffective or when certain types of symptoms are present like insomnia.
2.1.4.2. Olanzapine
Pollack investigated olanzapine augmentation to fluoxetine at a mean dose of 8.7 mg daily
and reported that olanzapine may be helpful for patients who fail to respond to SSRIs alone,
considering the advers events like wight gain (Pollack et al., 2006).
2.1.4.3. Aripiprazole
Two studies demonstrate that aripiprazole has promise in augmentation at dosages starting
at 10 mg daily (Menza et al., 2007; Hoge et al., 2008).
2.1.4.4. Risperidone
Adjunctive risperidone could be tried in patients with poor response at titrated doses up to
3 mg daily (Brawman-Mintzer et al., 2005; Simon et al., 2006).
2.1.4.5. Ziprasidone
Ziprasidone at a daily dose range of 20 to 80 mg may be helpful for patients with GAD who
did not have an adequate response to other medication treatment (Snyderman et al., 2005).
2.1.5. Other drugs
2.1.5.1. Azapirones
Buspirone was approved for the treatment of GAD more than 20 years ago. In recent years,
multiple members of the azapirone class, which comprises the partial or full 5-HTIA ago‐
nists gepirone, zalospirone, and ipsapirone, have been studied. These molecules show anx‐
iolytic properties but have limitations in terms of tolerability. In a recent brief report,
Mathew et al. tested the short-term tolerability and efficacy of PRX-00023, a nonazapirone 5-
HTIA selective partial agonist, in 23 outpatients with GAD (Mathew et al., 2008). This pre‐
liminary study indicated that PRX-00023 appeared to be generally well tolerated in patients
with GAD. But further investigations needed.
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2.1.5.2. Riluzole
Although double-blind, placebo-controlled trials are lacking, several open label trials have
suggested that riluzole, either as monotherapy or as augmentation of standard therapy, re‐
duces symptoms of some psychiatric disorders including generalized anxiety disorder
(Grant et al., 2007; Mathew et al., 2005).
Mathew et al.,investigated the efficacy and safety of treatment with riluzole (100 mg/day): of
the 15 patients who completed the trial, 12 had a rapid improvement of anxiety symptomatolo‐
gy (Mathew et al., 2005). Recently, Mathew et al. (2008), in an open-label trial, used proton mag‐
netic resonance spectroscopic imaging (1H MRSI) to examine the effects of the glutamate-
release inhibitor riluzole on hippocampal N-acetylaspartate (NAA), a neuronal marker, in 14
patients with GAD. Investigators demonstrated a relationship between hippocampal NAA
and symptom alleviation after the administration of riluzole in patients for 8 weeks; this result
suggested that riluzole might be efficacious for GAD (and subtypes of mood disorders) in part
because of reduced glutamate excitotoxicity and enhancement of hippocampal neuroplastici‐
ty. In studies of psychiatrically ill patients conducted to date, the drug has been quite well tol‐
erated; common adverse effects include nausea and sedation. Elevation of liver function tests is
common and necessitates periodic monitoring. Riluzole may hold promise for the treatment of
several psychiatric conditions, possibly through its ability to modulate pathologically dysre‐
gulated glutamate levels, and merits further investigation (Pittenger et al., 2008).
2.2. Nonpharmacological strategies; Psychotherapy
2.2.1. Cognitive behavioral therapy
One of the most successful psychosocial treatments for the treatment of GAD is cognitive-be‐
havioral therapy (CBT). The components of this therapy may vary to include the following: ed‐
ucation about the symptoms and causes of anxiety, cognitive restructuring, applied relaxation,
increasing awareness, learning to monitor of anxious symptoms presenting as physical symp‐
toms, and the automatic thoughts of worry created from situational and behavioral cues. Pa‐
tients are taught to manage these symptoms through training in arousal reduction techniques
such as pleasant imagery and diaphragmatic breathing; and imaginal and in vivo exposure to
anxiety cues coupled with copings skill rehearsal (Roemer et al; 2002).
A Cochrane collaboration review concluded that current evidence demonstrates that CBT is
effective for the short-term management of GAD relative to wait-list control but not active
supportive therapy or supportive treatment (ie, active supportive therapies underpinned by
humanistic principals). The most successful CBT treatment protocols have included motiva‐
tional therapy, interpersonal psychotherapy, integrative CBT (ICBT) to treat GAD (Baer,
2003). Although CBT is the most effective of the psychological treatments available for GAD,
available data indicate that a clinical response occurs in less than 50% of people receiving
CBT, so unmet needs still remain (Hunot et al., 2007).
One promising form of psychotherapy emphasizes the promotion of positive emotional
states and active coping behaviors, rather than focusing on how to reduce symptoms. This
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resilience-building treatment is referred to as “well-being therapy” and appears to be supe‐
rior to CBT on some measures in treatment-resistant GAD and other forms of anxiety (Fava
et al., 2005).
2.2.2. Mindfulness based cognitive therapy
A number of approaches have integrated features of Buddhist mindfulness practices with
CBT to treat a number of psychiatric disorders including GAD (Baer 2003). Mindfulness was
conceptualized as being a set of skills that can be learned independently of any spiritual or
cultural tradition and then applied to help manage psychiatric symptoms. These approaches
have included mindfulness based stress reduction (MBSR) (Kabat-Zinn 1982, 2003), mindful‐
ness based cognitive therapy (MBCT) (Segal et al. 2002), dialectical behavior therapy (DBT)
for borderline personality disorders (Linehan 1993a, b), and acceptance and commitment
therapy (ACT) mostly for anxiety and major mood disorders (Hayes et al. 1999).
There are two objectives associated with classical mindfulness (CM) skill training for treat‐
ing GAD: (1) to achieve a level of sustained, detailed, non-conceptual divided attention and
awareness (also known as bare attention or direct experience), and (2) develop the ability to
carry out experiential based insight based on the way of experiencing as described in (1).
These two objectives clearly imply that there are two major stages of mindfulness practice.
The first stage is training in sustaining, detailed, nonconceptual divided attention and
awareness which needs to be distinguished as significantly different from MBSR practice of
mindfulness. The second stage involves the reinstatement of gradual application of discrimi‐
native processes informed by direct experience in order to enrich the process of knowing
(Rapgay et al., 2011).
MBCT may be an acceptable and potentially effective treatment for reducing anxiety and
mood symptoms and increasing awareness of everyday experiences in patients with GAD.
Future directions include development of a randomized clinical trial of MBCT for GAD
(Evans et al., 2008).
2.3. Combination strategies
CBT in combination with a sub-therapeutic dose of diazepam produces a greater effect than
the same dose of diazepam alone (Power, et al., 1989). Given that GAD has a chronic course
and is often comorbid with depression it may be that the combined treatment of medication
and psychotherapy may provide an important treatment option that could lead to improved
outcomes beyond monotherapy (Barlow, 2002). Unfortunately, at this time there is no data
to support this conclusion.
3. Conclusion
GAD is a prevalent and disabling disorder that may appear with physical and psychiatric
comorbitidies. SSRIs and SNRIs defined as first line treatment options in GAD, and there is
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increasing interest in enhancement new strategies to deal with the disorder. Novel antide‐
pressants agomelatine and bupropion, atypical antipsychotics and anticonvulsants are
promising in the treatment of GAD but still far from expectations because the necessity of
close monitoring and some adverse events. Pharmacological interventions are still the most
effective interventions to manage the disorder while augmentation strategies promising.
However clinicians still in need of more effective treatment options that have rapid effect
and safe.
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